Acute conjunctivitis treatment market is growing due to the increase in ophthalmic disease prevalence rate, rising in investments for the development of new products, growing conscious health, funded eye check-up of acute conjunctivitis treatment. Moreover, increasing awareness of various eye infections and increasing prevalence among geriatric population boosting the market growth of acute conjunctivitis treatment. However, due to the stringent regulations in drug developmental process and side effects it would be difficult to understand whether or not this would be the case.
A sample of this report is available upon request @
Acute conjunctivitis treatment market is segmented on the basis of type, dosage form, drug class, distribution channel, and geography
Based on the type, acute conjunctivitis treatment is segmented as:
- Viral conjunctivitis
- Bacterial conjunctivitis
- Allergic conjunctivitis
- Conjunctivitis Caused by Irritants
Based on dosage form, acute conjunctivitis treatment is segmented as:
- Gels and cream
- Eye drops
- Tablets and Capsules
Based on the drug class, acute conjunctivitis treatment is segmented as:
- anti Histamines
- Antibiotic
- Mast cell stabilizers
- Anti-inflammatory drugs
- Others
Based on distribution channel , acute conjunctivitis treatment is segmented as:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
To view TOC of this report is available upon request @
Barry and Amir A. Azari in 2013, which was published in Journal of American Medical Association (JAMA), states that bacterial conjunctivitis accounts for about 50% of cases of conjunctivitis in US and thus estimated the bacterial conjunctivitis incidence rate was estimated at 135 in 10,000.Top pharma companies are dominating the market, such as sale, strong global presence, and efficient distribution network, R & D investments, superior quality products, and strong brand image. In 2016, Irish based pharmaceutical company Shire’s Xiidra received US FDA approval which is used to treat dry-eye. In 2015, Bausch & Lomb Inc. acquired Doctor’s Allergy Formula in order to expand its ophthalmic product portfolio,
Need more information about this report @
On the basis of geographical regions, acute conjunctivitis market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Pharmaceutical companies are emerging in R & D investments. The European market is the second largest market for acute conjunctivitis treatment. Increase in prevalence and growing awareness of conjunctivitis and its treatments are leading the growth of Asia Pacific acute conjunctivitis treatment market. The Middle East and Africa acute conjunctivitis treatment market is expected to have limited growth because of traditional healthcare practices and slow adoption of new products and therapies.
Some of the players in global acute conjunctivitis treatment market are Pfizer, Inc. (U.S), Allergan Inc. (Ireland), Boehringer Ingelheim GmbH (Germany), CIBA Vision Ophthalmics (U.S), Sanofi (France), Novartis AG (Switzerland), Bausch & Lomb Inc. (Valeant) (Canada), Merck & Co., Inc. (U.S), and Santen Pharmaceuticals Co. Ltd.(Japan).
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): 1-866-598-1553